School of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
J Ethnopharmacol. 2012 Jul 13;142(2):531-8. doi: 10.1016/j.jep.2012.05.033. Epub 2012 Jun 1.
Xiao-Qing-Long-Tang (XQLT) has been used for centuries in Asia to effectively treat patients with bronchial asthma.
We previously found that single and multiple doses of XQLT administered to sensitized mice before allergen challenge resulted in suppressed airway hyper-responsiveness and airway inflammation. In this study we aimed to investigate whether XQLT has the potential to attenuate the severity of asthma symptoms, and immunomodulatory mechanism of XQLT in a repetitive Dermatogoides pteronyssinus (D. pteronyssinus)-challenged chronic asthmatic mice model.
BALB/c mice were intratracheally (i.t.) inoculated with five doses of D. pteronyssinus (50 μl, 1mg/ml) and orally administered of XQLT (1 g/kg) at 1-week intervals. At three days after the last challenge, mice were sacrificed to evaluate airway remodeling, inflammation, lung histological features, and the expression profiles of cytokines and various genes.
XQLT significantly reduced bronchial inflammatory cell infiltration and airway remodeling. It inhibited D. pteronyssinus-induced total IgE and D. pteronyssinus-specific IgG1 in serum, and changed the "T(H)2-bios" in BALF by inhibiting the activation of NF-κB. Collagen assay and Histopathology indicated that XQLT reduced airway remodeling in the lung. Simultaneously, the RT-PCR analysis showed that XQLT downregulated IL-10, IL-13, RANTES, Eotaxin, and MCP-1 mRNA expression in the lung. Moreover, EMSA and immunohistochemistry staining demonstrated that XQLT inhibited NF-κB expression in the nucleus of bronchial epithelial cells.
These results suggest that XQLT exhibits anti-airway inflammatory, anti-airway remodeling, and specific immunoregulatory effects in a chronic asthmatic mice model.
小青龙汤(XQLT)在亚洲已使用了几个世纪,用于有效治疗支气管哮喘患者。
我们之前发现,在过敏原攻击前给予致敏小鼠单次和多次 XQLT 剂量,可导致气道高反应性和气道炎症受到抑制。在这项研究中,我们旨在研究 XQLT 是否具有减轻哮喘症状严重程度的潜力,以及 XQLT 在反复变应性粉尘螨(D. pteronyssinus)激发的慢性哮喘小鼠模型中的免疫调节机制。
BALB/c 小鼠通过气管内(i.t.)接种五剂量 D. pteronyssinus(50 μl,1mg/ml),并在 1 周间隔口服 XQLT(1 g/kg)。在最后一次攻击后三天,处死小鼠以评估气道重塑、炎症、肺组织学特征以及细胞因子和各种基因的表达谱。
XQLT 显著减少了支气管炎症细胞浸润和气道重塑。它抑制了血清中 D. pteronyssinus 诱导的总 IgE 和 D. pteronyssinus 特异性 IgG1,并通过抑制 NF-κB 的激活改变了 BALF 中的“T(H)2-生物”。胶原测定和组织病理学表明,XQLT 减少了肺中的气道重塑。同时,RT-PCR 分析表明,XQLT 下调了肺中 IL-10、IL-13、RANTES、Eotaxin 和 MCP-1mRNA 的表达。此外,EMSA 和免疫组织化学染色表明,XQLT 抑制了支气管上皮细胞核中的 NF-κB 表达。
这些结果表明,XQLT 在慢性哮喘小鼠模型中表现出抗气道炎症、抗气道重塑和特异性免疫调节作用。